Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Zogenix stock in Canada | $17.58

Own Zogenix shares in just a few minutes.

Zogenix, Inc
+$0.11 (+0.68%)

Zogenix is a biotechnology business based in the US. Zogenix stocks (ZGNX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.65 – a decrease of 5.64% over the previous week. Zogenix employs 218 staff and has a trailing 12-month revenue of around $26.1 million.

How to buy Zogenix stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ZGNX in this case.
  5. Research Zogenix stocks. The platform should provide the latest information available.
  6. Buy your Zogenix stocks. It's that simple.

How has Coronavirus impacted Zogenix's stock price?

Since the stock market crash in March caused by coronavirus, Zogenix's stock price has had significant negative movement.

Its last market close was $17.58, which is 41.71% down on its pre-crash value of $30.16 and 5.59% up on the lowest point reached during the March crash when the stocks fell as low as $16.65.

If you had bought $1,000 worth of Zogenix stocks at the start of February 2020, those stocks would have been worth $407.11 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $348.61.

Zogenix stock price

Use our graph to track the performance of ZGNX stocks over time.

Zogenix stocks at a glance

Information last updated 2021-07-30.
Latest market close$17.58
52-week range$15.9 - $25.88
50-day moving average $17.5721
200-day moving average $19.0893
Wall St. target price$48.22
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.32

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Zogenix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Zogenix price performance over time

Historical closes compared with the last close of $17.58

1 month (2021-07-02) -0.90%
3 months (2021-04-30) -6.93%

Zogenix financials

Revenue TTM USD$26.1 million
Gross profit TTM USD$-124,901,000
Return on assets TTM -23.82%
Return on equity TTM -61.99%
Profit margin 0%
Book value $5.756
Market capitalisation USD$904.7 million

TTM: trailing 12 months

How to short and sell Zogenix stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ZGNX.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 8.0 million Zogenix stocks held short by investors – that's known as Zogenix's "short interest". This figure is 0.6% down from 8.1 million last month.

There are a few different ways that this level of interest in shorting Zogenix stocks can be evaluated.

Zogenix's "short interest ratio" (SIR)

Zogenix's "short interest ratio" (SIR) is the quantity of Zogenix stocks currently shorted divided by the average quantity of Zogenix stocks traded daily (recently around 1.3 million). Zogenix's SIR currently stands at 6.25. In other words for every 100,000 Zogenix stocks traded daily on the market, roughly 6250 stocks are currently held short.

However Zogenix's short interest can also be evaluated against the total number of Zogenix stocks, or, against the total number of tradable Zogenix stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zogenix's short interest could be expressed as 0.14% of the outstanding stocks (for every 100,000 Zogenix stocks in existence, roughly 140 stocks are currently held short) or 0.1787% of the tradable stocks (for every 100,000 tradable Zogenix stocks, roughly 179 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Zogenix.

Find out more about how you can short Zogenix stock.

Zogenix stock dividends

We're not expecting Zogenix to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Zogenix stocks ever split?

Zogenix stocks were split on a 1:8 basis on 1 July 2015. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zogenix stocks – just the quantity. However, indirectly, the new 700% higher stock price could have impacted the market appetite for Zogenix stocks which in turn could have impacted Zogenix's stock price.

Zogenix stock price volatility

Over the last 12 months, Zogenix's stocks have ranged in value from as little as $15.9 up to $25.88. A popular way to gauge a stock's volatility is its "beta".

ZGNX.US volatility(beta: 1.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zogenix's is 1.3977. This would suggest that Zogenix's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Zogenix overview

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site